Nurix Therapeutics Inc NRIX

$22.99 -0.35 (-1.50%)

Valuation

Market cap
2,422,272,000
Revenue TTM
$83,980,000
Net income TTM
$-264,460,000
PE ratio
0.00
Forward PE
—
Profit margin
-314.91%
Debt to equity
0.00

Trading

Volume
815,500
Avg volume
1,286,904
Day's range
$22.85 – $23.75
Shares out
103,782,000
Stochastic %K
16%
Beta
1.82
Analysts
Strong Sell
Price target
$33.93

Price

Company profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and auto...

Show more

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 660 5320
Website
https://www.nurixtx.com
Address
1600 Sierra Point Parkway, Brisbane, United States

Latest news

Stocktwits

Merlintrader Sep 27, 7:54 AM
Can removing a protein change treatment? $CCCC, $KYMR, $NRIX, $RIGL C4 Therapeutics, Kymera, Nurix and Rigel reveal different paths from eliminating a protein to improving a patient’s outcome. Mechanism, tissue, evidence and retained rights determine the opportunity. https://www.merlintrader.com/protein-degradation-protacs-cccc-kymr-nrix-rigl/
0 replies
NVDAMillionaire Sep 22, 11:56 AM
$NRIX Brilliant piece that captures NRIX's situation perfectly. So if you want to update your understanding of NRIX or get to know NRIX better, this is essential reading. https://everyticker.com/quote/NRIX/analysis/nurix-therapeutics-roche-partnership-derisks-the-core-but-clinical-execution-will-define-the-stock-nasdaq-nrix
0 replies
oaksapollo Sep 18, 6:59 PM
$NRIX So far degrader-antibody conjugates are looking like a spectacular flop. 3/3 discontinued (ORM-5029, ABBV-787, ORM-6151). Is Nurix barking up the wrong tree? @LongTrainRunning
1 replies
Anthonyde1793 Sep 9, 1:31 PM
$NRIX Anything can happen at anytime i wouldnt sell and take a chance on some big news before December. But its your money im waiting patiently, Roche isnt giving away 2.3 billion with 700 million upfront money if they didnt think the drug is definitely getting approved. And i wouldnt be surprised if NURIX gets bought out its relatively cheap.
1 replies
ChefBoyAreWeGonnaBeRich Aug 28, 5:51 PM
$RARE $NRIX DCAing on weakness
0 replies
S_Franconi Aug 21, 1:40 PM
$NRIX 839 watchers 08/21/26
0 replies
Ravbcentinal Aug 13, 10:57 PM
$NRIX
0 replies
MaverikIT Aug 12, 6:59 PM
$ATRC $NRIX $URGN new 52wk$ today
0 replies